Nasdaq

Belite Bio's Phase 3 DRAGON Trial for Tinlarebant Recommended to Continue Without Modifications by Data Safety Monitoring Board

DSMB recommends continuing Phase 3 DRAGON trial for Tinlarebant in Stargardt disease without modifications; completion expected Q4 2025. Tinlarebant has received Fast Track, Rare Pediatric Disease, ...
Nasdaq

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...
Business Wire

Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board ...

BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug ...
abcnews4

Courier Square Phase 3 moves forward: public input sought in redevelopment plans

CHARLESTON, S.C. (WCIV) — A major new chapter in Charleston’s urban development is taking shape as the City’s Board of Architectural Review considers the conceptual plans for Phase 3 of the Courier ...